Management of the signs and symptoms of acute overdosage should be handled in a manner consistent with that indicated for other muscarinic agonists: general supportive measures should be instituted. If medically indicated, atropine, an anti-cholinergic agent, may be of value as an antidote for emergency use in patients who have had an overdose of cevimeline. If medically indicated, epinephrine may also be of value in the presence of severe cardiovascular depression or bronchoconstriction. It is not known if cevimeline is dialyzable.
The recommended dose of cevimeline hydrochloride capsules is 30 mg taken three times a day. There is insufficient safety information to support doses greater than 30 mg tid. There is also insufficient evidence for additional efficacy of cevimeline hydrochloride at doses greater than
30 mg tid.
EVOXAC® is available as white, hard gelatin capsules containing 30 mg of cevimeline hydrochloride. EVOXAC® capsules have a white opaque cap and a white opaque body. The capsules are imprinted with “EVOXAC” on the cap and “30 mg” on the body with a black bar above “30 mg”. It is supplied in child resistant bottles of:
100 capsules (NDC 63395-201-13).
Store at 25°C (77°F) excursion permitted to 15°-30°C (59°-86°F)
Manufactured for :
Daiichi Sankyo, Inc.
Basking Ridge, NJ 07920
Revised 04/2018 Printed in U.S.A.
PRINCIPAL DISPLAY PANEL — 30 mg Capsule Bottle Label
|EVOXAC cevimeline hydrochloride capsule|
|Labeler — Daiichi Sankyo, Inc. (844277256)|
Revised: 06/2022 Daiichi Sankyo, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.